Immunization: vital progress, unfinished agenda.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
11 2019
Historique:
received: 05 06 2019
accepted: 06 09 2019
entrez: 8 11 2019
pubmed: 7 11 2019
medline: 19 11 2019
Statut: ppublish

Résumé

Vaccination against infectious diseases has changed the future of the human species, saving millions of lives every year, both children and adults, and providing major benefits to society as a whole. Here we show, however, that national and sub-national coverage of vaccination varies greatly and major unmet needs persist. Although scientific progress opens exciting perspectives in terms of new vaccines, the pathway from discovery to sustainable implementation can be long and difficult, from the financing, development and licensing to programme implementation and public acceptance. Immunization is one of the best investments in health and should remain a priority for research, industry, public health and society.

Identifiants

pubmed: 31695203
doi: 10.1038/s41586-019-1656-7
pii: 10.1038/s41586-019-1656-7
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

119-129

Subventions

Organisme : Medical Research Council
ID : MC_EX_MR/K011944/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_EX_MR/P024270/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A900_1122
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R005990/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R005990/2
Pays : United Kingdom
Organisme : Department of Health
ID : SRF-2009-02-07
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00026/2
Pays : United Kingdom
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MC_PC_17221
Pays : United Kingdom

Références

World Health Organization. Vaccines and Diseases https://www.who.int/immunization/diseases/en/ (2019).
Kaslow, D. C. et al. Vaccine candidates for poor nations are going to waste. Nature 564, 337–339 (2018).
pubmed: 30560957 doi: 10.1038/d41586-018-07758-3
Centers for Disease Control and Prevention (CDC). Ten great public health achievements—United States, 1900–1999. MMWR Morb. Mortal. Wkly. Rep. 48, 241–243 (1999).
Rappuoli, R., Black, S. & Bloom, D. E. Vaccines and global health: in search of a sustainable model for vaccine development and delivery. Sci. Transl. Med. 11, eaaw2888 (2019). The authors demonstrate how promising and much needed vaccines for global health fail to reach full development because of inadequate financial incentives, and propose mechanisms to overcome this problem.
pubmed: 31217336 doi: 10.1126/scitranslmed.aaw2888
Rappuoli, R., Mandl, C. W., Black, S. & De Gregorio, E. Vaccines for the twenty-first century society. Nat. Rev. Immunol. 11, 865–872 (2011).
pubmed: 22051890 pmcid: 7098427 doi: 10.1038/nri3085
World Health Organization. Global Vaccine Action Plan 2011–2020 https://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/ (2013). This is the global reference for most national immunization programmes.
World Health Organization. State of the World’s Vaccines and Immunization. 3rd edition https://www.who.int/immunization/sowvi/en/ (2009).
Orenstein, W. A. & Ahmed, R. Simply put: vaccination saves lives. Proc. Natl Acad. Sci. USA 114, 4031–4033 (2017).
pubmed: 28396427 pmcid: 5402432 doi: 10.1073/pnas.1704507114
Bill & Melinda Gates Foundation. The Goalkeepers Report https://www.gatesfoundation.org/goalkeepers/report (2018).
Hammitt, L. L. et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob. Health 2, e397–e405 (2014).
pubmed: 25103393 pmcid: 5628631 doi: 10.1016/S2214-109X(14)70224-4
World Health Organization. Rubella vaccines: WHO position paper. Wkly. Epidemiol. Rec. 86, 301–316 (2011).
World Health Organization. Summary of WHO Position Paper on Measles (2017).
Chan, J. et al. Determining the pneumococcal conjugate vaccine coverage required for indirect protection against vaccine-type pneumococcal carriage in low and middle-income countries: a protocol for a prospective observational study. BMJ Open 8, e021512 (2018).
pubmed: 29776921 pmcid: 5961565 doi: 10.1136/bmjopen-2018-021512
Vynnycky, E. & White, R. An Introduction to Infectious Disease Modelling (OUP, 2010).
Guerra, F. M. et al. The basic reproduction number (R
pubmed: 28757186 doi: 10.1016/S1473-3099(17)30307-9
Aaby, P., Kollmann, T. R. & Benn, C. S. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat. Immunol. 15, 895–899 (2014).
pubmed: 25232810 doi: 10.1038/ni.2961
World Health Organziation. Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 — conclusions and recommendations. Wkly. Epidemiol. Rec. 89, 221–236 (2014).
Wilder-Smith, A. et al. The public health value of vaccines beyond efficacy: methods, measures and outcomes. BMC Med. 15, 138 (2017).
pubmed: 28743299 pmcid: 5527440 doi: 10.1186/s12916-017-0911-8
Bärnighausen, T., Bloom, D. E., Cafiero-Fonseca, E. T. & O’Brien, J. C. Valuing vaccination. Proc. Natl Acad. Sci. USA 111, 12313–12319 (2014).
pubmed: 25136129 pmcid: 4151736 doi: 10.1073/pnas.1400475111
Ozawa, S. et al. Return on investment from childhood immunization in low- and middle-income countries, 2011-20. Health Aff. (Millwood) 35, 199–207 (2016). The economic analysis in this paper of 10 vaccines administered in 73 low- and middle-income countries between 2011 and 2020 shows that a total of 20 million lives and over $350 billion could be saved, making vaccines a best buy in public health.
doi: 10.1377/hlthaff.2015.1086
Brenzel, L. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries? Vaccine 33 (Suppl. 1), A93–A98 (2015).
pubmed: 25919183 doi: 10.1016/j.vaccine.2014.12.076
Zhou, F. et al. Economic evaluation of the routine childhood immunization program in the United States, 2009. Pediatrics 133, 577–585 (2014).
pubmed: 24590750 doi: 10.1542/peds.2013-0698
Riumallo-Herl, C. et al. Poverty reduction and equity benefits of introducing or scaling up measles, rotavirus and pneumococcal vaccines in low-income and middle-income countries: a modelling study. BMJ Global Health 3, e000613 (2018).
pubmed: 29662691 pmcid: 5898318 doi: 10.1136/bmjgh-2017-000613
Chang, A. Y. et al. The equity impact vaccines may have on averting deaths and medical impoverishment in developing countries. Health Aff. (Millwood) 37, 316–324 (2018).
doi: 10.1377/hlthaff.2017.0861
Jit, M. et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Med. 13, 209 (2015). This paper considers the broader economic benefits around childhood development, household behaviour, and macro-economic indicators in addition to the usual microeconomic evaluations of immunization.
pubmed: 26335923 pmcid: 4558933 doi: 10.1186/s12916-015-0446-9
Smith, R. D., Keogh-Brown, M. R., Barnett, T. & Tait, J. The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment. Br. Med. J. 339, b4571 (2009).
doi: 10.1136/bmj.b4571
Putri, W. C. W. S., Muscatello, D. J., Stockwell, M. S. & Newall, A. T. Economic burden of seasonal influenza in the United States. Vaccine 36, 3960–3966 (2018).
pubmed: 29801998 doi: 10.1016/j.vaccine.2018.05.057
The World Bank. From Panic and Neglect to Investing in Health Security: Financing Pandemic Preparedness at a National Level https://www.worldbank.org/en/topic/pandemics/publication/from-panic-neglect-to-investing-in-health-security-financing-pandemic-preparedness-at-a-national-level (2017).
VoICE. The Value of Immunization Compendium of Evidence https://immunizationevidence.org/about/ (2019).
Grassly, N. C., Kang, G. & Kampmann, B. Biological challenges to effective vaccines in the developing world. Phil. Trans. R. Soc. Lond. B 370, 20140138 (2015). This article introduces a series of papers presented at a scientific meeting held at the Royal Society in London in 2015 that address the wide range of biological reasons for the variability in vaccine efficacy, such as age, sex, environment, genetics and co-infections.
doi: 10.1098/rstb.2014.0138
Permar, S., Levy, O., Kollman, T. R., Singh, A. & De Paris, K. Early life HIV-1 immunization: providing a window for protection before sexual debut. AIDS Res. Hum. Retroviruses 34, 823–827 (2018).
pubmed: 29860868 pmcid: 6204561 doi: 10.1089/aid.2018.0018
Lee, A. H. et al. Dynamic molecular changes during the first week of human life follow a robust developmental trajectory. Nat. Commun. 10, 1092 (2019).
pubmed: 30862783 pmcid: 6414553 doi: 10.1038/s41467-019-08794-x
Kobayashi, M. et al. Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries. F1000 Res. 5, 2355 (2016).
doi: 10.12688/f1000research.9363.1
Madhi, S. A. & Dangor, Z. Prospects for preventing infant invasive GBS disease through maternal vaccination. Vaccine 35, 4457–4460 (2017).
pubmed: 28237500 doi: 10.1016/j.vaccine.2017.02.025
Yen, L. M. & Thwaites, C. L. Tetanus. Lancet 393, 1657–1668 (2019).
pubmed: 30935736 doi: 10.1016/S0140-6736(18)33131-3
Munoz, F. M. et al. The Fourth International Neonatal and Maternal Immunization Symposium (INMIS 2017): Toward integrating maternal and infant immunization programs. mSphere 3, e00221-18 (2018).
pubmed: 30404933 pmcid: 6222055 doi: 10.1128/mSphere.00221-18
Westphal, D. W. et al. A protracted mumps outbreak in Western Australia despite high vaccine coverage: a population-based surveillance study. Lancet Infect. Dis. 19, 177–184 (2019).
pubmed: 30558994 doi: 10.1016/S1473-3099(18)30498-5
Fields, V. S. et al. Mumps in a highly vaccinated Marshallese community in Arkansas, USA: an outbreak report. Lancet Infect. Dis. 19, 185–192 (2019).
pubmed: 30635255 doi: 10.1016/S1473-3099(18)30607-8
Hotez, P. America and Europe’s new normal: the return of vaccine-preventable diseases. Pediatr. Res. 85, 912–914 (2019).
pubmed: 30812027 doi: 10.1038/s41390-019-0354-3
Alliance for Aging Research. The Silver Book®: Infectious Diseases and Prevention through Vaccination http://www.silverbook.org/publication/infectious-diseases/ (2013).
de Gomensoro, E., Del Giudice, G. & Doherty, T. M. Challenges in adult vaccination. Ann. Med. 50, 181–192 (2018).
pubmed: 29338438 doi: 10.1080/07853890.2017.1417632
International Federation on Ageing. World Coalition on Adult Vaccination https://www.ifa-fiv.org/project/adult-immunization-advocacy-2/ (2019).
Kim, D. K., Riley, L. E., Harriman, K. H., Hunter, P. & Bridges, C. B. Recommended immunization schedule for adults aged 19 years or older, United States, 2017. Ann. Intern. Med. 166, 209–219 (2017).
pubmed: 28166560 doi: 10.7326/M16-2936
National Health Service. Vaccinations; Vaccines Given to Adults https://www.nhs.uk/conditions/vaccinations/?tabname=adults (accessed 1 September 2019).
Bridges, C. B. et al. Meeting the challenges of immunizing adults. Vaccine 33 (Suppl. 4), D114–D120 (2015).
pubmed: 26615170 doi: 10.1016/j.vaccine.2015.09.054
Phillips, D. E., Dieleman, J. L., Lim, S. S. & Shearer, J. Determinants of effective vaccine coverage in low and middle-income countries: a systematic review and interpretive synthesis. BMC Health Serv. Res. 17, 681 (2017).
pubmed: 28950899 pmcid: 5615444 doi: 10.1186/s12913-017-2626-0
Leidner, A. J. et al. Cost-effectiveness of adult vaccinations: a systematic review. Vaccine 37, 226–234 (2018). This paper provides insights into the biological challenges to advance the concept of a life course of vaccination.
pubmed: 30527660 pmcid: 6545890 doi: 10.1016/j.vaccine.2018.11.056
Derhovanessian, E. & Pawelec, G. Vaccination in the elderly. Microb. Biotechnol. 5, 226–232 (2012).
pubmed: 21880118 pmcid: 3815782 doi: 10.1111/j.1751-7915.2011.00283.x
Public Health England. Complete Routine Immunisation Schedule https://www.gov.uk/government/publications/the-complete-routine-immunisation-schedule (2019).
Centers for Disease Control and Prevention. Vaccines & Immunizations https://www.cdc.gov/vaccines/index.html (2016).
Public Health England. Immunisation of Healthcare and Laboratory Staff: the Green Book, Chapter 12 https://www.gov.uk/government/publications/immunisation-of-healthcare-and-laboratory-staff-the-green-book-chapter-12 (2013).
Sarkar, S., Zlojutro, A., Khan, K. & Gardner, L. Measles resurgence in the USA: how international travel compounds vaccine resistance. Lancet Infect. Dis. 19, 684–686 (2019).
pubmed: 31079949 doi: 10.1016/S1473-3099(19)30231-2
CEPI. The Coalition for Epidemic Preparedness Innovations https://cepi.net/ (2019).
Butler, D. Translational research: crossing the valley of death. Nature 453, 840–842 (2008).
pubmed: 18548043 doi: 10.1038/453840a
Winslow, R. L. et al. Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored Ebola vaccines at 1 year. J. Am. Med. Assoc. 317, 1075–1077 (2017).
doi: 10.1001/jama.2016.20644
Snoy, P. J. Establishing efficacy of human products using animals: the US food and drug administration’s “animal rule”. Vet. Pathol. 47, 774–778 (2010).
pubmed: 20551476 doi: 10.1177/0300985810372506
Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 389, 505–518 (2017).
pubmed: 28017403 pmcid: 5364328 doi: 10.1016/S0140-6736(16)32621-6
Akanmori, B., Bellah, A., Ward, M. & Rago, L. The African vaccine regulatory forum (AVAREF): a platform for collaboration in a public health emergency. WHO Drug Inf. 29, 127–132 (2015).
Kallenberg, J. et al. Gavi’s transition policy: moving from development assistance to domestic financing of immunization programs. Health Aff. (Millwood) 35, 250–258 (2016).
doi: 10.1377/hlthaff.2015.1079
World Health Organization. Assessment Report of the Global Vaccine Action Plan: Strategic Advisory Group of Experts on Immunization https://apps.who.int/iris/handle/10665/276967 (2018). This is the annual update on the state of immunization in the world, with a wealth of data.
World Health Organization. Immunization, Vaccines and Biologicals. Data, Statistics and Graphics https://www.who.int/immunization/monitoring_surveillance/data/en/ (2019).
Findlow, J. Vaccines for the prevention of meningococcal capsular group B disease: what have we recently learned? Hum. Vaccin. Immunother. 12, 235–238 (2016).
pubmed: 26619037 doi: 10.1080/21645515.2015.1091131
World Health Organization. Malaria Vaccine Pilot Launched in Malawi https://www.who.int/news-room/detail/23-04-2019-malaria-vaccine-pilot-launched-in-malawi (2019).
Roland, D. Malaria vaccine: GSK’s thirty-year quest to eradicate a global killer. Telegraph (8 October 2013).
Larson, H. J., Hartigan-Go, K. & de Figueiredo, A. Vaccine confidence plummets in the Philippines following dengue vaccine scare: why it matters to pandemic preparedness. Hum. Vaccin. Immunother. 15, 625–627 (2019).
pubmed: 30309284 doi: 10.1080/21645515.2018.1522468
Clark, A. et al. Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials. Lancet Infect. Dis. 19, 717–727 (2019).
pubmed: 31178289 pmcid: 6595176 doi: 10.1016/S1473-3099(19)30126-4
Burdin, N., Handy, L. K. & Plotkin, S. A. What is wrong with pertussis vaccine immunity? The problem of waning effectiveness of pertussis vaccines. Cold Spring Harb. Perspect. Biol. 9, a029454 (2017).
pubmed: 28289064 pmcid: 5710106 doi: 10.1101/cshperspect.a029454
Khan, M. I. et al. Barriers to typhoid fever vaccine access in endemic countries. Res. Rep. Trop. Med. 8, 37–44 (2017).
pubmed: 30050343 pmcid: 6034652
Wilder-Smith, A. et al. Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. Lancet Infect. Dis. 19, e31–e38 (2019).
pubmed: 30195995 doi: 10.1016/S1473-3099(18)30494-8
Cabico, G. K. How the Dengvaxia scare helped erode decades of public trust in vaccines. Philstar Global Corp. (6 February 2019).
Plotkin, S., Robinson, J. M., Cunningham, G., Iqbal, R. & Larsen, S. The complexity and cost of vaccine manufacturing — an overview. Vaccine 35, 4064–4071 (2017). An important paper to help to understand the complexity and cost of vaccine manufacturing.
pubmed: 28647170 pmcid: 5518734 doi: 10.1016/j.vaccine.2017.06.003
Poland, G. A., Ovsyannikova, I. G. & Jacobson, R. M. Personalized vaccines: the emerging field of vaccinomics. Expert Opin. Biol. Ther. 8, 1659–1667 (2008).
pubmed: 18847302 pmcid: 2831634 doi: 10.1517/14712598.8.11.1659
Poland, G. A., Ovsyannikova, I. G., Jacobson, R. M. & Smith, D. I. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin. Pharmacol. Ther. 82, 653–664 (2007).
pubmed: 17971814 doi: 10.1038/sj.clpt.6100415
Mentzer, A. J., O’Connor, D., Pollard, A. J. & Hill, A. V. Searching for the human genetic factors standing in the way of universally effective vaccines. Phil. Trans. R. Soc. Lond. B 370, 20140341 (2015).
doi: 10.1098/rstb.2014.0341
UNICEF & World Health Organization. Progress and Challenges with Achieving Universal Immunization Coverage https://www.who.int/immunization/monitoring_surveillance/who-immuniz.pdf?ua=1 (2019).
UNICEF & World Health Organization. Progress Towards Global Immunization Goals – 2018  https://www.who.int/immunization/monitoring_surveillance/SlidesGlobalImmunization.pptx?ua=1 (2019).
World Health Organization. Immunization Coverage https://www.who.int/en/news-room/fact-sheets/detail/immunization-coverage (2019).
Berkley, S. Vaccination lags behind in middle-income countries. Nature 569, 309 (2019).
pubmed: 31089234 doi: 10.1038/d41586-019-01494-y
Hill, H. A., Elam-Evans, L. D., Yankey, D., Singleton, J. A. & Kang, Y. Vaccination coverage among children aged 19-35 months - United States, 2017. MMWR Morb. Mortal. Wkly. Rep. 67, 1123–1128 (2018).
pubmed: 30307907 pmcid: 6181261 doi: 10.15585/mmwr.mm6740a4
Zimlich, R. How Many Kids are Completely Unvaccinated? https://www.contemporarypediatrics.com/pediatrics/how-many-kids-are-completely-unvaccinated (2018).
Gong, W. et al. Comparison of three rapid household survey sampling methods for vaccination coverage assessment in a peri-urban setting in Pakistan. Int. J. Epidemiol. 48, 583–595 (2018).
doi: 10.1093/ije/dyy263
Cutts, F. T., Izurieta, H. S. & Rhoda, D. A. Measuring coverage in MNCH: design, implementation, and interpretation challenges associated with tracking vaccination coverage using household surveys. PLoS Med. 10, e1001404 (2013).
pubmed: 23667334 pmcid: 3646208 doi: 10.1371/journal.pmed.1001404
Lam, E., McCarthy, A. & Brennan, M. Vaccine-preventable diseases in humanitarian emergencies among refugee and internally-displaced populations. Hum. Vaccin. Immunother. 11, 2627–2636 (2015).
pubmed: 26406333 pmcid: 4685677 doi: 10.1080/21645515.2015.1096457
World Health Organization Regional Office for Europe. Measles in Europe: Record Number of Both Sick and Immunized http://www.euro.who.int/en/media-centre/sections/press-releases/2019/measles-in-europe-record-number-of-both-sick-and-immunized (2019).
European Centre for Disease Prevention and Control. Monthly Measles and Rubella Monitoring Report, April 2019 https://ecdc.europa.eu/en/publications-data/monthly-measles-and-rubella-monitoring-report-april-2019 (2019).
The Lancet. Measles, war, and health-care reforms in Ukraine. Lancet 392, 711 (2018).
pubmed: 30191812 doi: 10.1016/S0140-6736(18)31984-6
World Health Organization Regional Office for Europe. Over 100,000 People Sick With Measles in 14 Months: with Measles Cases at an Alarming Level in the European Region, WHO Scales up Response http://www.euro.who.int/en/media-centre/sections/press-releases/2019/over-100-000-people-sick-with-measles-in-14-months-with-measles-cases-at-an-alarming-level-in-the-european-region,-who-scales-up-response (2019).
Mosser, J. F. et al. Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000–2016: a spatial and temporal modelling study. Lancet 393, 1843–1855 (2019). This paper shows that the monitoring of vaccine coverage over time, at local rather than national levels, is crucial for programme management, improvement and for implementing operational approaches that enhance vaccine coverage equity.
pubmed: 30961907 pmcid: 6497987 doi: 10.1016/S0140-6736(19)30226-0
Murray, J. Vaccines by air as drone medicine service takes off in Ghana. The Guardian (25 April 2019).
World Health Organization. Immunization, Vaccines and Biologicals: Global Routine Immunization Strategies and Practices (GRISP) https://www.who.int/immunization/programmes_systems/policies_strategies/GRISP/en/ (2019).
GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1736–1788 (2018).
doi: 10.1016/S0140-6736(18)32203-7
US Department of Health and Human Services. Biomedical Advanced Research and Development Authority https://www.phe.gov/about/barda/Pages/default.aspx (2019).
Panteli, D. & Edwards, S. Ensuring Access to Medicines: How to Stimulate Innovation to Meet Patients’ Needs? (eds Richardson, E. et al.) (World Health Organization Regional Office for Europe, 2018).
McNeil, D. G. Jr. Polio cases surge in Pakistan and Afghanistan. The New York Times (2019).
DW NEWS. Pakistani Government Suspends Polio Vaccination Drives https://www.dw.com/cda/en/pakistani-government-suspends-polio-vaccination-drives/av-48677882 (2019).
World Health Organization. Report of the SAGE Working Group on Vaccine Hesitancy https://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf (2014).
European Centre for Disease Prevention and Control. Rapid Literature Review on Motivating Hesitant Population Groups in Europe to Vaccinate https://ecdc.europa.eu/en/publications-data/rapid-literature-review-motivating-hesitant-population-groups-europe-vaccinate (2015).
European Commission. The State of Vaccine Confidence in the EU: 2018 https://www.vaccineconfidence.org/research/the-state-of-vaccine-confidence-in-the-eu-2018/ (2018).
The Wellcome Trust. Wellcome Global Monitor 2018 — Chapter 5: Attitudes to Vaccines https://wellcome.ac.uk/reports/wellcome-global-monitor/2018/chapter-5-attitudes-vaccines (2019). This is one of the largest studies to evaluate of people’s attitudes, interest, trust and beliefs about science including immunization.
Lane, S., MacDonald, N. E., Marti, M. & Dumolard, L. Vaccine hesitancy around the globe: Analysis of three years of WHO/UNICEF Joint Reporting Form data-2015–2017. Vaccine 36, 3861–3867 (2018).
pubmed: 29605516 pmcid: 5999354 doi: 10.1016/j.vaccine.2018.03.063
Cohet, C. et al. Safety of AS03-adjuvanted influenza vaccines: a review of the evidence. Vaccine 37, 3006–3021 (2019).
pubmed: 31031030 doi: 10.1016/j.vaccine.2019.04.048
Karafillakis, E. & Larson, H. J. The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations. Vaccine 35, 4840–4850 (2017). This systematic review of vaccination risk perceptions and concerns published between 2004 and 2014 across Europe shows that the main concern was vaccine safety, followed by perceptions of low risk of contracting the vaccine-preventable diseases and, if contracted, that they were not severe.
pubmed: 28760616 doi: 10.1016/j.vaccine.2017.07.061
World Health Organization. Vaccine Safety Net https://www.who.int/vaccine_safety/initiative/communication/network/vaccine_safety_websites/en (2019).
London School of Hygiene & Tropical Medicine. The State of Vaccine Confidence 2015 https://www.vaccineconfidence.org/research/2015-vaccine-confidence (2015). This was the first benchmark report by the Vaccine Confidence Project, providing an overview on the key issues affecting confidence globally.
Sridhar, S. et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N. Engl. J. Med. 379, 327–340 (2018).
pubmed: 29897841 doi: 10.1056/NEJMoa1800820
UNICEF & World Health Organization. Situation Report 8: Measles Outbreak https://reliefweb.int/report/philippines/unicef-who-philippines-measles-outbreak-situation-report-8-2-april-2019 (2019).
Gavi. Gavi Board Starts Framing Alliance’s Approach to 2021–2025 Period https://www.gavi.org/library/news/press-releases/2018/gavi-board-starts-framing-alliance-s-approach-to-2021-2025-period/ (2018).
Bloom, D. E., Black, S., Salisbury, D. & Rappuoli, R. Antimicrobial resistance and the role of vaccines. Proc. Natl Acad. Sci. USA 115, 12868–12871 (2018).
pubmed: 30559204 pmcid: 6305009 doi: 10.1073/pnas.1717157115
Klugman, K. P. & Black, S. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc. Natl Acad. Sci. USA 115, 12896–12901 (2018).
pubmed: 30559195 pmcid: 6304973 doi: 10.1073/pnas.1721095115
Sevilla, J. P., Bloom, D. E., Cadarette, D., Jit, M. & Lipsitch, M. Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR. Proc. Natl Acad. Sci. USA 115, 12911–12919 (2018).
pubmed: 30559203 pmcid: 6305008 doi: 10.1073/pnas.1717161115
Plotkin, S. L. & Plotkin, S. A. in Plotkin’s Vaccines 7th edn (eds Plotkin, S. A. et al.) 1–15 (Elsevier, 2018).

Auteurs

Peter Piot (P)

Office of the Director, Vaccine Centre and Vaccine Confidence Project, London School of Hygiene & Tropical Medicine, London, UK. peter.piot@lshtm.ac.uk.

Heidi J Larson (HJ)

Office of the Director, Vaccine Centre and Vaccine Confidence Project, London School of Hygiene & Tropical Medicine, London, UK.
Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Centre for the Evaluation of Vaccination (CEV), University of Antwerp, Antwerp, Belgium.

Katherine L O'Brien (KL)

Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

John N'kengasong (J)

Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.

Edmond Ng (E)

Office of the Director, Vaccine Centre and Vaccine Confidence Project, London School of Hygiene & Tropical Medicine, London, UK.

Samba Sow (S)

Center for Vaccine Development, Bamako, Mali.

Beate Kampmann (B)

Office of the Director, Vaccine Centre and Vaccine Confidence Project, London School of Hygiene & Tropical Medicine, London, UK.
MRC Unit The Gambia at the LSHTM, Banjul, The Gambia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH